Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

AMM Eggermont; M Kicinski; CU Blank; M Mandala; GV Long; VG Atkinson; S Dalle; AM Haydon; A Meshcheryakov; A Khattak; MS Carlino; SK Sandhu; SSP Sarda; PA Ascierto; P Lorigan; D Grebennik; N Ibrahim; SI Marreaud; S Suciu; C Robert

doi:10.1016/j.annonc.2022.07.930

Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

AMM Eggermont
, M Kicinski
, CU Blank
, M Mandala
, GV Long
, VG Atkinson
, S Dalle
, AM Haydon
, A Meshcheryakov
, A Khattak
, MS Carlino
, SK Sandhu
, SSP Sarda
, PA Ascierto
, P Lorigan
, D Grebennik
, N Ibrahim
, SI Marreaud
, S Suciu
, C Robert

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S912-S913
Number of pages	2
Journal	Annals of Oncology
Volume	33
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2022.07.930
Publication status	Published - Sept 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2022.07.930

Cite this

Eggermont, AMM., Kicinski, M., Blank, CU., Mandala, M., Long, GV., Atkinson, VG., Dalle, S., Haydon, AM., Meshcheryakov, A., Khattak, A., Carlino, MS., Sandhu, SK., Sarda, SSP., Ascierto, PA., Lorigan, P., Grebennik, D., Ibrahim, N., Marreaud, SI., Suciu, S., & Robert, C. (2022). Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial. Annals of Oncology, 33(7), S912-S913. https://doi.org/10.1016/j.annonc.2022.07.930

@article{95b3cca1f89346d0a9dae2674d13b50d,

title = "Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial",

author = "AMM Eggermont and M Kicinski and CU Blank and M Mandala and GV Long and VG Atkinson and S Dalle and AM Haydon and A Meshcheryakov and A Khattak and MS Carlino and SK Sandhu and SSP Sarda and PA Ascierto and P Lorigan and D Grebennik and N Ibrahim and SI Marreaud and S Suciu and C Robert",

year = "2022",

month = sep,

doi = "10.1016/j.annonc.2022.07.930",

language = "English",

volume = "33",

pages = "S912--S913",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

number = "7",

}

Eggermont, AMM, Kicinski, M, Blank, CU, Mandala, M, Long, GV, Atkinson, VG, Dalle, S, Haydon, AM, Meshcheryakov, A, Khattak, A, Carlino, MS, Sandhu, SK, Sarda, SSP, Ascierto, PA, Lorigan, P, Grebennik, D, Ibrahim, N, Marreaud, SI, Suciu, S & Robert, C 2022, 'Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial', Annals of Oncology, vol. 33, no. 7, pp. S912-S913. https://doi.org/10.1016/j.annonc.2022.07.930

TY - JOUR

T1 - Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

T2 - 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

AU - Eggermont, AMM

AU - Kicinski, M

AU - Blank, CU

AU - Mandala, M

AU - Long, GV

AU - Atkinson, VG

AU - Dalle, S

AU - Haydon, AM

AU - Meshcheryakov, A

AU - Khattak, A

AU - Carlino, MS

AU - Sandhu, SK

AU - Sarda, SSP

AU - Ascierto, PA

AU - Lorigan, P

AU - Grebennik, D

AU - Ibrahim, N

AU - Marreaud, SI

AU - Suciu, S

AU - Robert, C

PY - 2022/9

Y1 - 2022/9

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000866211601075&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.annonc.2022.07.930

DO - 10.1016/j.annonc.2022.07.930

M3 - Meeting Abstract

SN - 0923-7534

VL - 33

SP - S912-S913

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

ER -

Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial

UN SDGs

Access to Document

Other files and links

Cite this